US Pharma MarketingMediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop treatments for fibro-inflammatory diseases.
Source: Pharmaceutical Technology